These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 22219190)

  • 21. Discovery and SAR of novel 4-thiazolyl-2-phenylaminopyrimidines as potent inhibitors of spleen tyrosine kinase (SYK).
    Farmer LJ; Bemis G; Britt SD; Cochran J; Connors M; Harrington EM; Hoock T; Markland W; Nanthakumar S; Taslimi P; Ter Haar E; Wang J; Zhaveri D; Salituro FG
    Bioorg Med Chem Lett; 2008 Dec; 18(23):6231-5. PubMed ID: 18938080
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New spleen tyrosine kinase inhibitors: patent applications published during 2011-2013.
    Thorarensen A; Kaila N
    Pharm Pat Anal; 2014 Sep; 3(5):523-41. PubMed ID: 25374321
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SH2 domain-mediated targeting, but not localization, of Syk in the plasma membrane is critical for FcepsilonRI signaling.
    Sada K; Zhang J; Siraganian RP
    Blood; 2001 Mar; 97(5):1352-9. PubMed ID: 11222380
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Syk-kinase inhibition prevents mast cell activation in nasal polyps.
    Patou J; Holtappels G; Affleck K; van Cauwenberge P; Bachert C
    Rhinology; 2011 Mar; 49(1):100-6. PubMed ID: 21468383
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comment on "Therapeutic targeting of Syk in autoimmune diabetes".
    Kapoor S
    J Immunol; 2011 Feb; 186(4):1885; author reply 1886-5. PubMed ID: 21289311
    [No Abstract]   [Full Text] [Related]  

  • 26. Steady state kinetics of spleen tyrosine kinase investigated by a real time fluorescence assay.
    Papp E; Tse JK; Ho H; Wang S; Shaw D; Lee S; Barnett J; Swinney DC; Bradshaw JM
    Biochemistry; 2007 Dec; 46(51):15103-14. PubMed ID: 18052078
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The 2010 patent landscape for spleen tyrosine kinase inhibitors.
    Moretto AF; Dehnhardt C; Kaila N; Papaioannou N; Thorarensen A
    Recent Pat Inflamm Allergy Drug Discov; 2012 May; 6(2):97-120. PubMed ID: 22292554
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Getting Syk: spleen tyrosine kinase as a therapeutic target.
    Geahlen RL
    Trends Pharmacol Sci; 2014 Aug; 35(8):414-22. PubMed ID: 24975478
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structural insights for design of potent spleen tyrosine kinase inhibitors from crystallographic analysis of three inhibitor complexes.
    Villaseñor AG; Kondru R; Ho H; Wang S; Papp E; Shaw D; Barnett JW; Browner MF; Kuglstatter A
    Chem Biol Drug Des; 2009 Apr; 73(4):466-70. PubMed ID: 19220318
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Spleen tyrosine kinase (Syk) inhibitor fostamatinib limits tissue damage and fibrosis in a bleomycin-induced scleroderma mouse model.
    Pamuk ON; Can G; Ayvaz S; Karaca T; Pamuk GE; Demirtas S; Tsokos GC
    Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S15-22. PubMed ID: 26148346
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The protein tyrosine kinase syk activity is reduced by clustering the mast cell function-associated antigen.
    Xu R; Pecht I
    Eur J Immunol; 2001 May; 31(5):1571-81. PubMed ID: 11465115
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel inhaled Syk inhibitor blocks mast cell degranulation and early asthmatic response.
    Ramis I; Otal R; Carreño C; Domènech A; Eichhorn P; Orellana A; Maldonado M; De Alba J; Prats N; Fernández JC; Vidal B; Miralpeix M
    Pharmacol Res; 2015 Sep; 99():116-24. PubMed ID: 26051661
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structure-activity relationship studies of imidazo[1,2-c]pyrimidine derivatives as potent and orally effective Syk family kinases inhibitors.
    Hirabayashi A; Mukaiyama H; Kobayashi H; Shiohara H; Nakayama S; Ozawa M; Tsuji E; Miyazawa K; Misawa K; Ohnota H; Isaji M
    Bioorg Med Chem; 2008 Oct; 16(20):9247-60. PubMed ID: 18823784
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Novel Triazolopyridine-Based Spleen Tyrosine Kinase Inhibitor That Arrests Joint Inflammation.
    Ferguson GD; Delgado M; Plantevin-Krenitsky V; Jensen-Pergakes K; Bates RJ; Torres S; Celeridad M; Brown H; Burnett K; Nadolny L; Tehrani L; Packard G; Pagarigan B; Haelewyn J; Nguyen T; Xu L; Tang Y; Hickman M; Baculi F; Pierce S; Miyazawa K; Jackson P; Chamberlain P; LeBrun L; Xie W; Bennett B; Blease K
    PLoS One; 2016; 11(1):e0145705. PubMed ID: 26756335
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting the SYK-BTK axis for the treatment of immunological and hematological disorders: recent progress and therapeutic perspectives.
    Tan SL; Liao C; Lucas MC; Stevenson C; DeMartino JA
    Pharmacol Ther; 2013 May; 138(2):294-309. PubMed ID: 23396081
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Syk inhibitors with high potency in presence of blood.
    Thoma G; Blanz J; Bühlmayer P; Drückes P; Kittelmann M; Smith AB; van Eis M; Vangrevelinghe E; Zerwes HG; Che JJ; He X; Jin Y; Lee CC; Michellys PY; Uno T; Liu H
    Bioorg Med Chem Lett; 2014 May; 24(10):2278-82. PubMed ID: 24726806
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Protein kinase inhibitors in the treatment of inflammatory and autoimmune diseases.
    Patterson H; Nibbs R; McInnes I; Siebert S
    Clin Exp Immunol; 2014 Apr; 176(1):1-10. PubMed ID: 24313320
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Structural basis for Syk tyrosine kinase ubiquity in signal transduction pathways revealed by the crystal structure of its regulatory SH2 domains bound to a dually phosphorylated ITAM peptide.
    Fütterer K; Wong J; Grucza RA; Chan AC; Waksman G
    J Mol Biol; 1998 Aug; 281(3):523-37. PubMed ID: 9698567
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery of dual ZAP70 and Syk kinases inhibitors by docking into a rare C-helix-out conformation of Syk.
    Zhao H; Caflisch A
    Bioorg Med Chem Lett; 2014 Mar; 24(6):1523-7. PubMed ID: 24569110
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intracellular single-chain variable fragments directed to the Src homology 2 domains of Syk partially inhibit Fc epsilon RI signaling in the RBL-2H3 cell line.
    Dauvillier S; Mérida P; Visintin M; Cattaneo A; Bonnerot C; Dariavach P
    J Immunol; 2002 Sep; 169(5):2274-83. PubMed ID: 12193692
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.